Chimeric antigen receptor (CAR)-T-cell therapy for glioblastoma: what can we learn from the early clinical trials? A systematic review.

Neurooncol Adv · 2025 · PMC12232909 · PMID 40626039

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

This may be significant as at least 2 studies reported here were based in China.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.